Company News Archive
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
This content is password protected. To view it please enter your password below: Password:
Australia: A Key Focus for Oncobeta
With one of the highest incidences of skin cancer in the world found here in Australia(1), OncoBeta, a commercial stage medical device company specialising in innovative epidermal radioisotope therapies, is…